Filing Flows › Health Care › NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · NewAmsterdam Pharma Co N.V. (NAMS) Q3 2026 earnings results →
Q3 2026 Revenue up 5407% year over year to $19.2M · 91¢ of every $1 of revenue lost · operating margin -230.6%
NewAmsterdam Pharma Co N.V. made $19.2M in Q3 2026 (55× Y/Y). Operating margin -230.6%, net loss $17.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $19.2M in Q3 2026, up 5407% year over year and up 418% from the previous quarter.
Operating costs exceeded revenue by $44.2M, an operating margin of -230.6%. Total costs grew 14% against revenue growth of 5407%. The fastest-growing cost line was Research & development (+27%). The quarter ended with a net loss of $17.4M, narrower than the previous quarter's $64.1M loss. Non-operating items added $28.0M, -173% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$39.8M. Non-cash charges added back $67K of depreciation and amortization and $12.5M of share-based compensation. Working capital and other items used $35.0M. Capital expenditures of $177K exceeded it, leaving free cash flow of −$40.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $19.2M | 55× | -230.6% | −$17.4M | −$39.8M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $3.7M | -81% | n/m | −$64.1M | −$39.2M |
| Q1 2026 | 10-Q | May 7, 2026 | $3.0M | +2% | n/m | −$48.4M | −$30.6M |
| Q4 2025 | 10-K | Feb 18, 2026 | $32K | -100% | n/m | −$74.9M | −$40.9M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $348K | -99% | n/m | −$72.0M | −$32.8M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $19.1M | +740% | -186.1% | −$17.4M | −$37.7M |
| Q1 2025 | 10-Q | May 8, 2025 | $3.0M | +113% | n/m | −$39.5M | −$36.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About NewAmsterdam Pharma Co N.V.
We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy. In multiple Phase 3 trials, we have investigated obicetrapib, an oral, low-dose, once-daily, highly selective cholesteryl ester transfer protein (“CETP”) inhibitor, alone or as a fixed-dose combination (“FDC”) with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease (“CVD”) with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
In its own words, from its 10-K, filed Feb 18, 2026.
NewAmsterdam Pharma Co N.V. against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 55× against the peers' median +10%. Operating margin: -230.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Co N.V. | Q3 2026 | $19.2M | 55× | -230.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: NewAmsterdam Pharma Co N.V. 10-Q on SEC EDGAR · CIK 1936258 · Pharmaceutical Preparations
More on NAMS
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results